Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.30 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29090621 | 1.00 | ALDH1A1 (0.41) | ALDH1A1TSHRHSD17B10TDP1LMNA | |
| Acetic Acid SCHEMBL27618719 | 0.96 | ALDH1A1 (0.38) | ALDH1A1TSHRHSD17B10TDP1LMNA | |
| SCHEMBL2158686 | 0.85 | SLC1A1 (0.37) | SLC1A1 | |
| SCHEMBL1396066 | 0.82 | ALDH1A1 (0.38) | ALDH1A1TSHRHSD17B10TDP1LMNA | |
| SCHEMBL2400319 | 0.82 | ALDH1A1 (0.38) | ALDH1A1TSHRHSD17B10TDP1LMNA | |
| SCHEMBL7748632 | 0.82 | SLC1A1 (0.30) | SLC1A1 | |
| SCHEMBL432874 | 0.81 | ALDH1A1 (0.41) | ALDH1A1TSHRHSD17B10TDP1LMNA | |
| SCHEMBL28788298 | 0.81 | ALDH1A1 (0.41) | ALDH1A1TSHRHSD17B10TDP1LMNA | |
| SCHEMBL13087404 | 0.81 | ALDH1A1 (0.41) | ALDH1A1TSHRHSD17B10TDP1LMNA | |
| SCHEMBL7092900 | 0.79 | ALDH1A1 (0.39) | ALDH1A1TSHRHSD17B10TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110381944-A | Substances for the treatment of fatty liver related disorders | 斯堪的比奥疗法有限公司 | 2019-10-25 | — | — | CN | claimed |
| CN-110088615-A | Detection and quantitative mass spectrometric determination method for renal function metabolin | 梅塔博隆股份有限公司 | 2019-08-02 | — | — | CN | claimed |
| CN-109563127-A | Diagnostic method, therapeutic agent and use thereof | 麦特博隆股份有限公司 | 2019-04-02 | — | — | CN | claimed |
| CN-109328018-A | Adjust the composition and method of the intracorporal phosphorus of companion animals or enzyme | 雀巢产品技术援助有限公司 | 2019-02-12 | — | — | CN | claimed |
| CN-109298115-A | A variety of metabolin quantitative detecting methods and metabolism chip in biological sample | 深圳市绘云生物科技有限公司 | 2019-02-01 | — | — | CN | claimed |
| CN-106362578-A | Flue gas treatment method | 徐明好 | 2017-02-01 | — | — | CN | claimed |
| EP-1750126-B1 | METHOD AND APPARATUS FOR ANALYZING AMINOFUNCTIONAL COMPOUND | AJINOMOTO KK (JP) | 2015-09-16 | — | — | EP | claimed |
| EP-2858638-A1 | ALLOSTERIC CHAPERONES AND USES THEREOF | Fondazione Telethon (IT) | 2015-04-15 | — | — | EP | claimed |
| WO-2013182652-A1 | ALLOSTERIC CHAPERONES AND USES THEREOF | FONDAZIONE TELETHON (IT) | 2013-12-12 | — | — | WO | claimed |
| CN-101437507-A | Oral preparation for sleep induction and oral preparation for improving stress insomnia | FANCL CORP (JP) | 2009-05-20 | — | — | CN | claimed |
| CN-101385857-A | Novel nano preparation with stable protein and preparation method and use thereof | UNIV CHINA PHARMA (CN) | 2009-03-18 | — | — | CN | claimed |
| US-5008372-A | Reacting with anhydrous trifluoroacetic acid | CORNELL RESEARCH FOUNDATION, INC. (US) | 1991-04-16 | — | — | US | claimed |
| EP-0142487-B1 | NOVEL ATRIAL PEPTIDES | WASHINGTON UNIVERSITY (US) | 1990-01-03 | — | — | EP | claimed |
| EP-0142487-A2 | Novel atrial peptides | WASHINGTON UNIVERSITY (US) | 1985-05-22 | — | — | EP | claimed |
| JP-11299491-A | — | — | None | — | — | JP | disclosed |
| US-20250339370-A1 | PERFORMANCE-ENHANCING EXCIPIENTS AND METHODS OF REDUCING VISCOSITY AND INCREASING STABILITY OF BIOLOGIC FORMULATIONS | AVANTOR PERFORMANCE MATERIALS, LLC (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4416135-A1 | HERBICIDES AND USE THEREOF | Projini Agchem Ltd (IL) | 2024-08-21 | — | — | EP | disclosed |
| EP-0142487-B1 | NOVEL ATRIAL PEPTIDES | WASHINGTON UNIVERSITY (US) | 1990-01-03 | — | — | EP | disclosed |
| EP-0142487-A2 | Novel atrial peptides | WASHINGTON UNIVERSITY (US) | 1985-05-22 | — | — | EP | disclosed |
| US-4389343-A | POLYPEPTIDES | HOFFMANN-LA ROCHE INC. (US) | 1983-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339370-A1 | PERFORMANCE-ENHANCING EXCIPIENTS AND METHODS OF REDUCING VISCOSITY AND INCREASING STABILITY OF BIOLOGIC FORMULATIONS | AADAT, KYNU, PNISR | ALDH1A1 3256/4885TSHR 3639/4885HSD17B10 3843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.